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Ultrastructure of noncnzymatically glycated mesangial matrix in dia-
betic nephropathy. Advanced protein glycation has been proposed as a
major factor in the development of diabetic nephropathy. Advanced
glycation end products (AGEs) have altered the structure of extracellular
matrix component and impaired self association in vitro. To elucidate the
role of AGEs in the progression of diabetic nephropathy, the present
study was undertaken to localize glomerular AGEs immunohistochemi-
cally. Ultrastructural changes of the mesangial matrix were analyzed with
high resolution scanning electron microscopy. No glomerular AGEs
staining was noted in normal control kidney specimens, or in tissue from
glomerulonephritis patients without diabetes mellitus. The mesangium
showed a positive AGEs staining in advanced stages of diabetic nephrop-
athy, and the most characteristic finding was the strong AGEs staining in
nodular lesions. By high resolution scanning electron microscopy, control
and diabetic mesangial matrices revealed a meshwork structure composed
of fine fibrils (10 nm in width) and numerous pores (12 to 13 nni in
diameter). In the nodular lesions, however, loosening of the meshwork
was significant, and the diameter of the pores was enlarged (approximately
24 nm). This study provides the first immunohistochemical evidence that
AGEs are localized in diabetic glomeruli, most notably to nodular lesions.
Advanced glycation might play a role in the progression of diabetic
nephropathy through impairment of the assembly of matrix proteins in
vivo.
Although it remains still controversial, available data indicate
that the development of diabetic nephropathy is linked to hyper-
glycemia [1, 2]. Glucose reacts nonenzymatically with proteins to
form Schiff base and Amadori products. Further incubation of
these early products leads to the formation of advanced glycation
end products (AGEs) that are characterized by fluorescence, a
brown color and cross linking [3, 4]. Protein modification by AGE
is expected to occur in proteins with relatively long half lives, such
as collagen [5], lens crystallins, and myelin [4]. Such a modification
occurs with normal aging and is accelerated in patients with
diabetes [2].
Recent immunohistochemical studies with anti-AGE antibod-
ies have demonstrated their presence in serum and in several
types of human tissues including arterial wall [6], brain [7] and
renal cortex [8]. However, AGEs have not been demonstrated
directly in diabetic glomerular lesions. Our anti-AGE antibody [9,
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10] reacts not only with AGE proteins such as AGE-bovine serum
albumin, AGE-human serum albumin and AGE-hemoglobin, but
also with AGE preparations obtained from such lysine derivatives
as a-tosyl-L-lysine and a-tosyl-L-lysine methyl ester, or from
monoaminocarboxylic acids such as e-aminocapronic acid, y-ami-
no-n-butyric acid and (3-alanine. Unmodified counterparts of
these preparations do not serve as antigens. Fructosyl-e-capronic
acid, a synthetic Amadori compound, and proposed AGE struc-
tures such as 2-(2-froyl)-4(5)-(2-furanyl)-1H-imidazole (FF1) [11],
pyrraline [12], and pentosidine [13] are not recognized as antigens
by our antibody [9]. Available data, therefore, suggest that our
antibody may react with a primary AGE structure common to
AGE preparations, although determination of its structure is
currently under way.
In the first stage of this study, we inununohistochemically
evaluated the localization of AGEs in the glomeruli from patients
with diabetic nephropathy using our anti-AGE antibody. Glyca-
tion seems to play a vital role in the association of matrix
interactions and causes changes in the extracellular matrix of a
diabetic patient [1, 2, 14]. Type IV collagen is the major compo-
nent of the matrix meshwork, and laminin, proteoglycans, fi-
bronectin, and entactin/nidogen together form the meshed struc-
ture of the extracellular matrix [15]. The development and
maintenance of a normal extracellular matrix depends on a
geometrically ordered self-assembly process involving site-spe-
cific, end-to-end, and lateral interactions of these macromolecules
[16—18]. Advanced protein glycation has been proposed as a
major factor in the development of complications via the forma-
tion of AGEs [1, 2, 14]. AGE modification of extracellular matrix
components may induce an alteration of structure and impair-
ment of self association in vitro [19, 20].
Since the first set of our experiments revealed AGE accumula-
tion in the mesangial matrix of the sclerosing glomeruli, in the
second set of experiments the ultrastructural changes of mesang-
ial matrix were examined using high resolution scanning electron
microscopy (HRSEM) [21, 22].
Methods
Patients
For immunohistochemical studies, we evaluated kidney speci-
mens from 10 patients with noninsulin-dependent diabetes mdli-
tus (NIDDM) and diabetic nephropathy with glomerulosclerosis
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Fig. 1. Immunohistoclwmical localization of advanced glycation end products (AGEs) by immunoperoxidase. A. No glomerular, tubular, or interstitial
staining for AGEs in a specimen from a 62-year-old patients with membranous nephropathy without diabetes mellitus. B. AGEs immunoreactivity can
be seen in the mesangial area of a kidney specimen from a 62-year-old diabetic patient. C. Intense AGEs immunoreactivity in a nodular lesion (arrow).
AGEs immunoreactivity also can be observed in the tubulus and interstitium in a kidney specimen from a 85-year-old diabetic patient. D. AGEs
immunoreactivity in the fibrous crescent of the Bowman's capsule of a scierosed glomerulus in a kidney specimen from a 85-year-old diabetic patient.
of valying degrees of severity. Eight specimens were obtained at
renal biopsy and two were obtained at autopsy from six men and
four women aged 43 to 85 years (mean 62 11 years). Proteinuria
varied in severity ranging from 0.9 to 13.8 g/day (mean 3.9 3.5
glday). Impairment of renal function was reflected by a serum
creatinine concentration ranging from 0.84 to 5.4 mg/dl (mean 1.8
1.4 mg/dl). As controls for immunohistochemical studies,
kidneys from three patients with no renal disease, that is, hema-
tuna, proteinuria or compromised renal functions and specimens
from five patients with glomerulonephritis but without diabetes
mellitus, were used.
Kidneys from five patients with NIDDM were used for electron
microscopy. Two of these patients were autopsy cases with
nephrotic syndrome due to advanced diabetic nephropathy, but
who had died of non-renal complications. The other three pa-
tients were biopsy cases with proteinuria, and frozen blocks used
for immunofluorescence studies were utilized. A total of 30
glomeruli were examined in autopsy specimens and 10 glomeruli
were examined in biopsy specimens. Specimens were stained with
hematoxylin and eosin, periodic acid-Schiff and periodic acid-
silver methenamine for light microscopy. The controls for electron
microscopic studies included kidneys from two age-matched au-
topsy cases with no renal disease, and the normal part of three
kidneys removed from patients with kidney tumor at surgery.
Preparation of anti-AGE-antibody
A mouse anti-AGE monoclonal antibody was prepared and its
immunoreactivity was described previously [9]. Briefly the splenic
lymphocytes from BALB/c mice were immunized with AGEs-
bovine serum albumin and were fused to myeloma P3U1 cells.
These hybrid cells were screened and cultured, and a cell line with
positive reactions to AGEs-human serum albumin, but negative
reactions to BSA, was selected through successive subclonings.
Antibody was produced in the ascitic fluid of BALB!c mice, and
was purified by DEAE-cellulose chromatography.
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Fig. 2. Transmission electron micrograph of acellular glomendus from controls (A, B) and patients with diabetic nephropathy (C, D). A. All cellular
components have been completely removed, retaining the in situ architecture. x2,000. B. Partial enlargement of A (large arrow) demonstrating a fibriltar
mesangial matrix (MM; X6O,000). C. Note the increase in the mesangial matrix (*; X2,000). D, Higher magnification of the fibrillar mesangial matrix.
Note many bundles of collagen fibers (small arrows) which are embedded within the mesangial matrix. (X60,000). Abbreviations are: CL, capillary
lumen; US, urinary space; GBM, glomerular basement membrane.
Immunohistochemical procedures
The distribution of AGEs was studied by immunoperoxidase
techniques using the avidin-biotin method [23]. Formalin-fixed
and paraffin-embedded tissue was cut into 4-i.tm thick sections and
deparaffinized by treatment with xylene (5 mm, 3 times), followed
by graded ethanol. Nonspecific protein binding sites were blocked
by incubating the tissue sections with 1% fetal calf serum in
Tris-buffered snline for 20 minutes. Nonspecific staining was
blocked by 15 minutes of incubation with avidin and biotin
solutions (Vector Lab., Buarlingame, CA, USA), respectively.
These sections were then washed with phosphate-buffered saline
(PBS) and dipped in 0.3% H202-100% methanol for 20 minutes
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Fig. 3. High resolution scanning electron micrograph of a control acellulargiomerulus. A. The glomerular basement membrane appears (GBM) as a thin,
single-layered sheet with a smooth surface except for in the wrinkling mesangial area. The epithelial surface of the GBM is smooth. Endothelial surfaces
are irregular in the centrolobular zones, where the mesangial matrix (*) appears as a fenestrated septum (X4,800). B. Partial enlargement of A (large
arrow), demonstrating the meshwork structure of the mesangial matrix composed of pores (arrowheads) and strands (small arrows). Note the fine fibrils
over the stomata (large arrows; x81,000). Abbreviations are: CL, capillary lumen; US, urinary space.
to block endogenous peroxidase. The slides were first stained with
a biotin-labeled mouse anti-AGE monoclonal antibody in a
humidity chamber for two hours at 37°C. Slides were washed with
0.5% Tween/PBS followed by PBS. The slides were then incu-
bated with avidin biotinylated horseradish peroxidase (Vector
Lab.). Next, the slides were washed in PBS and then a color
reaction was performed by incubating the slides with freshly
prepared 3,3-diaminobenzidine (DAB) reagent until the staining
was complete. The reaction was stopped by placing the slides into
water. After washing in PBS, Meyer hematoxylin was added as a
counterstain. As an additional control, positively stained tissues
were subjected to a blocking experiment in which they were
preincubated with unlabeled anti-AGE serum. Sections preincu-
bated with anti-AGE serum remained uniformly unstained.
Preparation of acellular renal cortex
Acellular cortical tissues were prepared as has been described
previously [24, 25] from five patients with NIDDM and two
controls, and studied by the following transmission and scanning
electron microscopy. Briefly, renal cortical tissue blocks were
minced to 2 mm3. Minced tissue specimens were sequentially
exposed to 4 mrvi ethylenediamine tetraacetic acid (24 hr, 4°C),
3% Triton X-100 (24 hr, 4°C), 0.05% deoxyribonuclease (Type I,
Sigma, St. Louis, MO, USA) in 1 M NaCI (24 hr, 4°C), and 4%
sodium deoxycholate (2 to 4 hr, room temperature). All solutions
contained 0.1% sodium azide. Tissue specimens were rinsed
extensively between each step with distilled water. Acellular renal
cortical specimens were separated for transmission and scanning
electron microscopy preparation.
Tissue preparation for transmission electron microscopy
Acellular renal cortical specimens were immersed into 2.5%
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2, 2 hr, 4°C),
post-fixed in 0.1 M osmium tetroxide (2 hr 4°C), and then
embedded in Epon following dehydration in a graded series of
ethanol preparations. Thin sections were stained with uranyl
acetate and lead citrate and examined with a transmission elec-
tron microscope (Hitachi H7100, Japan) at 75 kV.
Tissue preparation for scanning electron microscopy
Acellular renal cortical specimens were prepared for high
resolution scanning electron microscopy by tannic acid conductive
staining as has been described previously [22, 26]. Briefly, speci-
mens were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.2, 2 hr, 4°C). After rinsing with the same buffer, the
tannin-osmium conductive staining [27] was performed as follows:
specimens were immersed three times in 1% osmium tetroxide (2
hr, 4°C), and interposed by 2% tannic acid solution (pH 4.2, 2 hr,
room temperature). Between each step, rinses were performed at
least three times with distilled water. Following staining, the
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Fig. 4. High resolution scanning electron micrograph of an acellular glomerulus from a patient with diabetic nephropathy. A. Note the narrowing of the
capillary lumen (CL) due to the expansion of the mesangial matrix (MM; X3,200). B. Higher magnification of the mesangial matrix demonstrating the
meshwork structure of the mesangial matrix with numerous pores of varying sizes composed of strands (small arrows). Note small pores (arrowheads)
and larger pores (triangle arrowheads), and globular clusters (*; X 198,000). US is urinary space.
specimens were dehydrated in a graded series of ethanol prepa-
rations and cryofractured in liquid nitrogen. Cryofractured spec-
imens were transferred to t-butyl alcohol, and freeze-dried with a
vacuum evaporator (ID-2, Eiko, Japan). The dried specimens
were then mounted on aluminum stubs, and examined with an
HRSEM (S-900, Hitachi) without metal coating, at original
magnifications ranging from X 250 to 200,000, using an accelerat-
ing voltage of 20 kV.
Motphometric and statistical analyses
Morphometric analyses of high-resolution scanning electron
micrographs were performed as has been described previously
[26]. Micrographs were selected for measurements when the
meshwork structure could be observed via the en face view at
higher magnifications in order to "flatten" the basement mem-
brane surface and to reduce secondary errors caused by its
waviness. Measurements of the meshwork's strands and pores
were made using these micrographs. The long diameter of the
pores and the perpendicular width of the strands were measured
with an ocular micrometer equipped with a 0.1 mm scale. Finally,
the mean value and standard deviation for each parameter were
determined after the diameter of 100 pores and the width of 50
strands had been measured. Statistical significance was analyzed
using the Student's t-test and the Cocrane Welch test. A P value
of < 0.05 was considered significant.
Results
Immunohistochemical localization of AGEs
AGEs were hardly stained in the renal cortex specimens from
normal kidneys and from patients with glomerulonephritis with-
out diabetes mellitus (Fig. 1A). However, slight AGE staining was
observed in the glomerular mesangium and tubulus of patients
with the early stages of diabetic nephropathy. AGEs were stained
in the mesangium and the capillary and the staining of the
mesangium in particular increased with the progression of gb-
merulosclerosis (Fig. 1B). The most characteristic finding in
diabetic patients was strong AGE staining in the nodular lesions
(Fig. 1C). Bowman's capsule and periglomerular fibrosis in scle-
rosing gbomeruli became positive for AGE staining (Fig. 1D).
AGE staining was also observed in the renal artery. Also noted
were AGE staining in tubular, peritubular, and extracellular
matrix, and the extents of the staining increased in the more
advanced cases.
Transmission electron microscopic findings
Following treatment with a series of detergents, all cellular
components were completely removed, while the GBM and
mesangial matrix remained intact (Fig. 2). The mesangial matrix
was less electron-dense than the GBM, and was clearly distin-
guishable from the GBM. In controls, the mesangial matrix was
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Fig. 5. High resolution scanning electron micrograph of an acellular nodular lesion (NOD) from a patient with diabetic nephropathy. Note the rough surface
of the nodular lesion (X 16,800). GBM is glomerular basement membrane.
confined to the centro-lobular regions and appeared discontinu-
ous when observed with a transmission electron microscope (Fig.
2A). At higher magnifications, the mesangial matrix appeared to
be less compact than the GBM, and revealed a fine fibrillar
structure (Fig. 2B). Globules were observed on these fibrils. Very
few bundles of banded collagen fibers were observed and mesh-
work formation was not clear.
In specimens from diabetic patients, an expansion of the
mesangial area and an increase in the mesangial matrix were both
observed (Fig. 2C). Wrinkling of the GBM was observed in the
mesangial portion. At higher magnifications, the fibrous structure
of the mesangial matrix could be observed (Fig. 2D). Globules
were noted mainly at the intersection of the fibrils. Abundant
collagen fibers among the mesangial matrix were observed in
some specimens. A few collagen fibers were located in parallel
with one another (Fig. 2D).
Scanning electron microscopic findings
On HRSEM examination, the mesangial matrix extended onto
the endothelial surface of the GBM and appeared as a series of
anastomosing ridges (Fig. 3A). At higher magnification, the
mesangial matrix appeared to consist of an irregular, loosely
meshed structures composed of relatively uniform strands ranging
from 3 to 18 nm wide (mean SD 10.4 3.3 nm). The pores
demonstrated fairly uniform diameters ranging from 4 to 28 nm
(mean SD 13.0 5.3 nm; Fig. 3B). In portions, thin bridging
fibrils were observed over the stomata.
In specimens from diabetic patients, increases in the mesangial
matrix and thickening of the GBM could be observed clearly. The
mesangial regions were occupied with the mesangial matrix and
expanded to the peripheral capillaries, and there also was narrow-
ing of the capillary lumens (Fig. 4A). At higher magnifications, the
meshwork structure, which was composed of strands, became
evident (Fig. 4B). The widths of these strands were relatively
uniform (mean SD 10.5 2.7 nm). These strands generally
branched and anastomosed with neighboring strands at short
intervals, but some straight and curvilinear strands also were
observed. The diameters of the pores were variable (mean SD
14.0 6.1 nm), however, statistically they did not differ from
those of the controls. Globular clusters also were noted on the
matrix surface, which might be adhesion plaques.
An acellular nodular lesion also was observed (Fig. 5). At
higher magnifications the loose meshwork structure appeared to
be composed of various sized strands ranging from 6 nm to 24 nm
(mean SD 11.4 3.8 nm; Fig. 6). Occasionally some thick fibers
were noted to be running parallel among the strands, correspond-
ing to the transmission electron micrograph image (Fig. 2D). The
pore sizes were variable, ranging from 4 nm to 70 nm (mean SD
23.6 12.3 nm), and were statistically larger than those of the
controls.
Figure 7 illustrates histograms of the distribution of strand
widths and pore diameters measured in the mesangial matrix of a
normal control, a diabetic patient and a patient with nodular
lesions.
Discussion
In this investigation, we were able to demonstrate immunohis-
tochemically the preferential localization of AGEs to nodular
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Fig. 6. Higher magnification of the nodular lesion (Fig. 5, large arrow). Note many thick collagen fibers (large arrows) among the loose meshwork
composed of small pores (arrowheads), larger pores (triangle arrowheads), and strands (small arrows) (X 168,000).
lesions of patients with diabetic glomerulosclerosis. Furthermore,
the looser meshwork structures of these lesions were visualized
using HRSEM.
Concerning the role of glycation in the diabetic kidney, Mitsu-
hashi et al [281 have reported the increased content of AGE in the
renal cortex of a streptozotocin-induced diabetic rat in their
immunochemical study. Miyata and Monnier [8] have demon-
strated pyrraline only in the fibrous crescent areas of the glomer-
uli or obliterated glomeruli. On the other hand, our antibody,
although it did not react with pyrraline [9], detected AGEs in
non-obliterated glomeruli and an expanded mesangial matrix,
especially in nodular lesions.
High resolution scanning electron microscopy, equipped with a
field emission source, a very short objective lens, and a resolving
power of 0.5 nm at 30 kV [21], made it possible to observe the
three-dimensional ultrastructure of the GBM. These HRSEM
studies from our laboratory [22, 26, 29—31] and others [32, 33]
clearly demonstrate the meshwork and pores of the basement
membranes. In our previous investigation, we observed the polyg-
onal meshwork structures not only in the GBM [22, 26, 29—31],
but also in the tubular basement membrane [26, 31], Bowman's
capsule basement membrane, and the peritubular capillary base-
ment membrane [26]. The strands averaged 6 to 7 nm wide,
whereas the pore sizes within the meshwork were variable and
differed according to the basement membrane type. The strands in
the mesangial matrix were a little wider than those of other
basement membranes in the kidney. The pores in the mesangial
matrices also were larger compared with those of the GBM. By
transmission electron microscopy, the mesangial matrix appears
more coarsely fibrillar and less electron dense [34]. These differ-
ences might be due to the dissimilarity of components of the
extracellular matrix. Both the GBM and the mesangial matrix
tn ;
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Fig. 7. Hthtograms of pore diameter and strand width selected in the mesangial matrices representing one control (A, D), one patient with diabetes (B, E),
and a nodular patient (C, F).
contain type IV collagen, laminin, entactin, nidogen and heparan
sulfate proteoglycan [15]. The following additional components,
including fibronectin [35, 36], amyloid-P component [37], actomy-
osin [35], and chondroitin sulfate proteoglycans [38], are localized
exclusively in the mesangial matrix. Mundel et al [34] have
observed abundant microfibrils with a mean thickness of 15 nm in
the mesangial matrix by transmission electron microscopy using
tannic acid. They have suggested that the ubiquitous distribution
of fibronectin within the mesangial matrix is due to the corre-
sponding distribution of microfibrils.
In diabetics, various compositional changes of matrix proteins
have been studied extensively. Biochemical and immunohisto-
chemical studies have indicated an increase in the normal constit-
uents of the matrix, such as type IV collagen, and fibronectin [39,
40], and a decrease [41] or no change [42] in heparan sulfate
proteoglycans in cases of early diabetes. However, in cases of
progressive glomeruloscierosis, decreases in type IV collagen [39,
40] and heparan sulfate proteoglycans [42,43] have been observed
in immunohistochemical studies. Immunohistochemically, in the
late stages, minor components or components not normally
present in the mesangial matrix (such as type III, type V, and type
VI collagen) may increase [39, 40, 44].
Following the removal of cellular components, many collagen
fibers were observed in the mesangial matrix by transmission
electron microscopy. Thick fibers observed in the mesangial
matrix by HRSEM, which corresponded to transmission electron
micrograph findings appeared to be type III or type V collagen.
Because type V and type VI collagens are the major components
of nodular lesions [39, 44], increases in these interstitial and fibril
or microfibril collagens may contribute to the formation of wider
strands in the mesangial matrix of a nodular lesion. As mesangial
cells are known to produce these extracellular matrix components
in vitro, phenotypic changes of the mesangial cell may be respon-
sible for change in these components [45].
These structural changes are accompanied by an impairment of
the associative properties of the basement membrane components
that reduces their ability to interact with each other to form an
ordered polymeric complex. Tarsio, Regfer and Furcht [46] have
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found that nonen2ymatic glycation of laminin and/or type IV
collagen significantly reduces the cooperative binding with hepa-
nfl. They have speculated that this is one of the causes of the
decrease in heparan sulfate proteoglycan in relation to the
proteinuria found in patients with diabetic nephropathy.
More recently, Anderson, Tsilibary and Charonis [33] have
examined structural changes in the bovine kidney tubular base-
ment membrane following in vitro nonenzymatic glycation. Using
high-resolution scanning electron microscopy, they have identified
an increase in the number of large openings in the meshwork, and
have concluded that nonenzymatic glycation and cross link for-
mation among basement membrane components might lead to
modifications of the basement membrane. The preferential local-
ization of AGEs in a nodular lesion suggests that AGEs might
cause porosity of the extracellular matrix in vivo. As no metallo-
protease that is specific for type VI collagen has been identified
thus far [47], AGEs formation might occur preferentially in type
VI collagen-rich nodular lesions, which are sites of slow turnover.
To our knowledge, we are the first to demonstrate the immu-
nohistochemical localization of AGEs in diabetic nodular lesions
and to provide morphologic evidence of the loose meshwork
structure of the mesangial matrix in diabetic patients in vivo.
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